Fosamax is a bisphosphonate (i.e., drug that inhibits bone thinning and deterioration) manufactured and marketed by Merck and approved by the FDA in 1995 primarily to treat and prevent osteoporosis. Since its release, Fosamax has been prescribed to hundreds of millions of individuals, predominately post-menopausal women. In these cases, plaintiffs primarily allege dental or jaw-related injuries including osteonecrosis (ONJ). The latter condition, also referred to as bisphosphonate-induced osteonecrosis ("BONJ"), is alleged to causes the jaw bone to die, resulting in severe pain and, often, significant disfigurement.
Next Liaison Counsel Meeting April 9, 2025 at 1:30pm EST in person in Courtroom 303 & Case Management Conference April 16, 2025 at 9:00am EST via a Zoom link provided by the court, unless otherwise notified by the court. An Agenda for the Case Management Conference shall be submitted to the court 7 days before the liaison counsel meeting.